Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single canter preliminary experience

Transplantation

Volumn 78, Issue 11, 2004, Pages 1683-1688

  Tan, Henkie P ^a,b   Kaczorowski, David J ^a   Basu, Amit ^a   Khan, Akhtar ^a   McCauley, Jerry ^a   Marcos, Amadeo ^a   Fung, John J ^a   Starzl, Thomas E ^a   Shapiro, Ron ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Campath; HIV; Living related renal transplantation; Steroid free immunosuppression

Indexed keywords

ALEMTUZUMAB; CD4 ANTIGEN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; COMORBIDITY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; LIVING DONOR; LOW DRUG DOSE; MALE; MONOTHERAPY; NEPHRECTOMY; PRIORITY JOURNAL; RECIPIENT; VIRUS LOAD;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CD4 LYMPHOCYTE COUNT; FEMALE; HIV SEROPOSITIVITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 10644270654     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000145880.38548.0D     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, www. cdc.gov/hiv/stats. htm#international, updated December 3, 2003.
2. Perinbasekar S, Brod-Miller C, Pal S, et al. Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 1996; 16: 280.
3. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 1998; 65: 1187.
4. Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15: 347.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853.
6. Roland ME, Lo B, Braff J, et al. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med 2003; 163: 1773.
7. Ratner LE, Cisek LJ, Moore RG, et al. Laparoscopic live donor nephrectomy. Transplantation 1995; 60: 1047.
8. Tan HP, Maley WR, Kavoussi LR, et al. Laparoscopic live donor nephrectomy: evolution of a new standard. Curr Opin Organ Transplant 2000; 12: 312.
9. Tan HP, Orloff M, Marcos A, et al. Laparoscopic live donor nephrectomy. Graft 2002; 5: 404.
10. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
11. Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238: 520.
12. Waldmann H. Apersonal history of the CAMPATH-1H antibody. Med Oncol 2002; 19: S3.
13. Shapiro R, Tan HP, Basu A, et al. Campath-1H preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients [abstract]. Am J Transplant 2004; 4: 405.
14. Shapiro R, Basu A, Tan HP, et al. Thymoglobulin preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients: An update [abstract]. Am J Transplant 2004; 4: 577.
15. Ifudu O, Salifu MO, Reydel C, et al. Survival of patients with AIDS and end-stage renal disease receiving hemodialysis. Dialysis and Transplantation 2004; 33: 176.
16. Murase N, Metes D, Zeevi A, et al. Immunomonitoring of liver recipients treated with tolerance-enhancing regimen of immunosuppression. Am J Transplant 2004; 4: 400.
17. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002; 110: 185.
18. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990; 49: 354.
19. Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13: 537.
20. Schwarz A, Offermann G, Keller F, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation - data on four cases and review of the literature. Transplantation 1993; 55: 95.
21. Swanson SJ, Kirk AD, Ko CW, et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4: 144.
22. Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370.
23. Hirose K, Baxter-Lowe LA, Carlson L, et al. Unexpectedly high rejection rates in HIV-positive recipients of renal transplants. Am J Transplant 2004; 4: 290.